Information Provided By:
Fly News Breaks for February 27, 2020
Feb 27, 2020 | 09:25 EDT
Roth Capital analyst Yasmeen Rahimi raised the firm's price target on Moderna to $33 from $24 and keeps a Buy rating on the shares. The analyst notes that with its Q4 update, the company continued to emphasize the de-risked nature of mRNA prophylactic vaccines and its strategic focus at making CMV the backbone of Moderna's future.
News For MRNA From the Last 2 Days
May 19, 2022 | 09:55 EDT
Notable gainers among liquid option names this morning include Synopsys (SNPS) $292.33 +19.76, Live Nation (LYV) $90.59 +5.20, Moderna (MRNA) $143.87 +6.16, Expedia (EXPE) $124.71 +4.56, and Freeport McMoRan (FCX) $36.45 +1.11.